Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neuroblastoma 8Prostatic Neoplasms 3Skin Neoplasms 2Sarcoma, Ewing 2Precancerous Conditions 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioma 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Typical Teratoid Rhabdoid Tumor 1Stomach Neoplasms 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Lymphoma, Follicular 1Lung Neoplasms 1Keratosis, Actinic 1Glioblastoma 1Gastritis, Atrophic 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Temozolomide 44Radiotherapy 20Magnetic Resonance Spectroscopy 13Irinotecan 13Carboplatin 11Bevacizumab 11Filgrastim 9Surgical Procedures, Operative 7Procarbazine 6sargramostim 5Vincristine 5Imatinib Mesylate 5Etoposide 5Erlotinib Hydrochloride 5Carmustine 5Biopsy 5etoposide phosphate 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Immunohistochemistry 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4temsirolimus 3poly ICLC 3aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Gadolinium DTPA 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligodendroglioma × Eflornithine × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡